What is SwipeRx?
SwipeRx operates within the Drug Stores & Pharmacies industry, employing between 100 to 249 individuals and generating between $1M to $5M in revenue. The company's focus on this essential sector, coupled with its recent substantial capital raises, indicates a strategic push towards scaling operations and enhancing its market presence. The consistent flow of investment suggests strong investor confidence in SwipeRx's business model and its potential for future expansion.
How much funding has SwipeRx raised?
SwipeRx has raised a total of $33.3M across 2 funding rounds:
Series A
$6.3M
Series B
$27M
Series A (2017): $6.3M with participation from IMJ Investment Partners, Unitus Impact, MDI Ventures, 500 Global, Kickstart Ventures, Endeavor, and Global Innovation Fund
Series B (2022): $27M led by Susquehanna International Group, Bill & Melinda Gates Foundation, MDI Ventures, and Johnson & Johnson Impact Ventures
Key Investors in SwipeRx
Susquehanna International Group
Susquehanna International Group is a global financial firm with expertise in securities markets and institutional clients, including venture capital and private equity specializations, indicating a strategic interest in SwipeRx's growth potential.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation, focused on improving health and reducing poverty, likely sees SwipeRx's operations as contributing to broader health accessibility and efficiency within its mission.
MDI Ventures
MDI Ventures is a global multi-stage venture capital firm focused on investing in local founders and startups, particularly in Indonesia, aiming to drive innovation and digital transformation across various sectors with an emphasis on social and environmental impact.
What's next for SwipeRx?
The substantial enterprise-level funding, particularly the recent strategic investment, positions SwipeRx for accelerated growth and market penetration. This capital infusion is likely to be directed towards expanding its service offerings, enhancing technological infrastructure, and potentially broadening its geographical reach. The company's progression through Series A and Series B financing rounds signifies a maturing business model poised for significant scaling and further development within the competitive pharmacy landscape.
See full SwipeRx company page
